Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy (PRINT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01299545
Recruitment Status : Terminated (Recruitment difficulties)
First Posted : February 18, 2011
Last Update Posted : February 1, 2013
Sponsor:
Collaborators:
Premier Research Group plc
Theradis pharma
Medpharmgene, Inc.
Information provided by (Responsible Party):
TcLand Expression S.A.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012